Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
28.41
+0.22 (+0.78%)
Streaming Delayed Price
Updated: 10:49 AM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Royalty Pharma Plc Cl A
< Previous
1
2
3
4
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
September 18, 2024
Via
Benzinga
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
September 16, 2024
Now could be a great time to scoop up three stocks trading way below their previous peaks.
Via
The Motley Fool
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
September 08, 2024
These dividend payers could more than double their payouts in the decade ahead.
Via
The Motley Fool
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
September 04, 2024
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company...
Via
Benzinga
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
August 16, 2024
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."
Via
Benzinga
NASDAQ:RPRX: good value for what you're paying.
April 24, 2024
Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
Looking Into Royalty Pharma's Recent Short Interest
April 04, 2024
Via
Benzinga
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
March 29, 2024
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals.
Via
Chartmill
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
July 11, 2024
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing.
Via
Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
June 26, 2024
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
June 12, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Royalty Pharma's Earnings: A Preview
February 14, 2024
Via
Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
June 05, 2024
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.
Via
InvestorPlace
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
May 28, 2024
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.
Via
Benzinga
Exposures
Product Safety
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
May 28, 2024
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug.
Via
Investor's Business Daily
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
May 23, 2024
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.
Via
Benzinga
7 Dividend Stocks to Buy at a 52-Week Low
May 20, 2024
For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low.
Via
InvestorPlace
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
May 02, 2024
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses...
Via
Benzinga
3 Pharma Stocks to Sell in April Before They Crash & Burn
April 11, 2024
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.
Via
InvestorPlace
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
April 09, 2024
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio.
Via
InvestorPlace
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
April 09, 2024
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April.
Via
InvestorPlace
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
March 27, 2024
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
Via
InvestorPlace
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
February 29, 2024
When you look at ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
February 16, 2024
Analysts are quite bullish about these beaten-down stocks.
Via
The Motley Fool
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
February 08, 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.
Via
InvestorPlace
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 08, 2024
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals.
Via
Chartmill
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.